IMR Press / FBL / Volume 7 / Issue 5 / DOI: 10.2741/A928

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Apoptosis in gliomas, and its role in their current and future treatment
Show Less
1 William and Karen Davidson Laboratory of Brain Tumor Biology, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
2 Laboratory of Molecular Neuro-Oncology, Department of Neurology, University of Tübingen, School of Medicine, Tübingen, Germany

Academic Editor: Van Meir

Front. Biosci. (Landmark Ed) 2002, 7(5), 339–353; https://doi.org/10.2741/A928
Published: 1 August 2002
(This article belongs to the Special Issue Encyclopedia of neuro-oncology)
Abstract

Apoptosis has recently entered the spotlight in the continuing search for new therapeutic approaches to cancer because it plays a twofold role in this disease. As stated by Lowe and Lin: “(M)ost cytotoxic anticancer agents induce apoptosis...(and so) the same mutations that suppress apoptosis during tumor development also reduce treatment sensitivity” (1). Therefore, any strategy aimed at increasing the propensity of glioma cells to undergo apoptosis could be therapeutic in its own right, but has the added potential of enhancing their sensitivity to other, established, treatments. As a corollary, understanding apoptotic mechanisms at the molecular level will not only help to explain why gliomas arise, but also identify points of intervention. This review will focus on these points, with emphasis on two families of apoptotic molecules, death ligands and their receptors, and BCL-2 family proteins. Near-term strategies of how apoptosis can be exploited therapeutically are discussed.

Keywords
Glioma
Hypoxia
Apoptosis
p21
Apo2L/TRAIL
CD95L
EGFR
Bcl-2
Bax
Review
Share
Back to top